Near-infrared (NIR) phosphors have received increasing attention for designing novel solid-state light sources with broadband NIR output. In this work, a novel NIR phosphor LiScP 2 O 7 :Cr 3+ (LSP:Cr 3+ ) is developed with the emissions (750−1100 nm) completely in the NIR spectral range. Under 470 nm excitation, LSP:0.06Cr 3+ shows broadband NIR emissions peaking at ∼880 nm, with a full width at half maximum (FWHM) of ∼170 nm and an internal quantum yield (IQY) of ∼38%. Moreover, photoluminescence (PL) improvements of LSP:Cr 3+ phosphors are achieved by Yb 3+ codoping, leading to the broadened FWHM (up to ∼210 nm), increased IQY (η max = ∼74%), and reduced thermal quenching. The energy transformation processes in LSP:Cr 3+ ,Yb 3+ are quantitatively analyzed on the basis of PL lifetime and QY measurements, revealing that the PL improvements by Yb 3+ codoping principally originate from the energy transfer from Cr 3+ to more efficient and thermally stable Yb 3+ emitters. Finally, NIR phosphor-converted light-emitting diodes (pc-LEDs) are fabricated by combining LSP:Cr 3+ ,Yb 3+ phosphors with blue LED chips, giving a maximum NIR output power of ∼36 mW and photoelectric efficiency of ∼12% at 100 mA drive current. The results suggest that the investigated phosphors would be promising luminescent converters for broadband NIR pc-LED applications.
BackgroundImmune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the potential biomarkers associated with response.MethodsIn this single-arm, open-label, phase II study, we enrolled stage IV BTC patients. Participants received camrelizumab (3 mg/kg) plus gemcitabine (800 mg/m2) and oxaliplatin (85 mg/m2). Primary endpoints were 6-month progression-free survival (PFS) rate and safety. Secondary endpoints were objective response rate (ORR), PFS and overall survival (OS). Exploratory endpoints included association between response and tumor mutational burden (TMB), blood TMB, dynamic change of ctDNA and immune microenvironment.Results54 patients with advanced BTC were screened, of whom 38 eligible patients were enrolled. One patient withdrew informed consent before first dose treatment. Median follow-up was 11.8 months. The 6-month PFS rate was 50% (95% CI 33 to 65). Twenty (54%) out of 37 patients had an objective response. The median PFS was 6.1 months and median OS was 11.8 months. The most common treatment-related adverse events (TRAEs) were fatigue (27 (73%)) and fever (27 (73%)). The most frequent grade 3 or worse TRAEs were hypokalemia (7 (19%)) and fatigue (6 (16%)). The ORR was 80% in patients with programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) ≥1% versus 53.8% in PD-L1 TPS <1%. There was no association between response and TMB, blood TMB, immune proportion score or immune cells (p>0.05), except that PFS was associated with blood TMB. Patients with positive post-treatment ctDNA had shorter PFS (p=0.007; HR, 2.83; 95% CI 1.27 to 6.28).ConclusionCamrelizumab plus GEMOX showed a promising antitumor activity and acceptable safety profile as first-line treatment in advanced BTC patients. Potential biomarkers are needed to identify patients who might respond to camrelizumab plus GEMOX.Trial registration numberNCT03486678.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.